Search the site

Scholarships

Find out more about the scholarship opportunities at the Wesfarmers Centre, including Training Scholarships and Higher Degree by Research Scholarships.

2018 Round 2 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful recipients for the 2018 Round 2 Seed Funding Grants. The Wesfarmers Centre Scientific

2018 Round 1 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful applications for the 2018 Round 1 Wesfarmers Centre Seed Funding. The Wesfarmers Centre

2016 Round 1 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the 4 successful applications for the 2016 Round 1 Wesfarmers Centre Seed Funding.

Resources

Wesfarmers Centre of Vaccines & Infectious Diseases resources

Rheumatic Heart Disease Endgame Strategy: what does it mean to community?

Across Australia, more than 5,000 Aboriginal and Torres Strait Islander people are currently living with rheumatic heart disease (RHD) or its precursor, acute rheumatic fever (ARF).

Australian Group on Antimicrobial Resistance surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns in Australian children and adolescents 2022 - 2023

Between January 2022 and December 2023, there were 1,827 bloodstream infection (BSI) isolates in 1,745 children and adolescents reported to the Australian Group on Antimicrobial Resistance (AGAR) surveillance outcome programs, with 40% of episodes in children aged < 12 months.

Perceived stress in mothers of children with and without islet and coeliac autoimmunity in the ENDIA study

We aimed to assess perceived stress and influencing factors in mothers with children at risk of type 1 diabetes and coeliac disease who did, or did not, develop islet autoantibodies or coeliac autoantibodies by 4 years of age.

Drug-resistant gram-negative bacterial infections in children in the Oceania region: review of the epidemiology, antimicrobial availability, treatment, clinical trial and pharmacokinetic

Gram-negative bacterial infections remain a major cause of morbidity and mortality in children and neonates globally, compounded by the rise of antimicrobial resistance. Barriers to paediatric antibiotic licencing lead to reduced availability of potentially effective agents for treatment. For children and neonates in the Oceania region, specific challenges remain including a paucity of surveillance data on local rates of antimicrobial resistance, and lack of availability of newer, more costly agents.

Evaluating the effectiveness of the 13-valent pneumococcal conjugate vaccine and clinical and demographic characteristics on pneumococcal carriage density in young children

High nasopharyngeal pneumococcal carriage density is associated with severe pneumonia; however, little is known about factors that affect pneumococcal carriage density including pneumococcal vaccination. We describe pneumococcal density by clinical and demographic factors, and effect of 13-valent pneumococcal conjugate vaccine (PCV13) on density in Papua New Guinea (PNG), Lao People’s Democratic Republic (Lao PDR) and Mongolia, 3–6 years following national PCV13 introduction.